Systematic Literature Review: Effectiveness of Insulin Combination Therapy with Glucagon-Like Peptide-1 (GLP-1) Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus

Benly Levi Andreas Sibarani; Putri Utami

doi:10.55927/ajha.v3i2.12310

Authors

Benly Levi Andreas Sibarani Regional Public Hospital of Muaradua, South OKU, South Sumatera
Putri Utami Medical Doctor Profession Program, Faculty of Medicine, University of Bengkulu

DOI:

https://doi.org/10.55927/ajha.v3i2.12310

Keywords:

Diabetes Mellitus, GLP-1, HbA1c, Incretin, Insulin

Abstract

Diabetes mellitus remains an evolving metabolic and endocrine disease. Effective pharmacological management of type 2 DM is still a global concern. Insulin therapy often causes side effects of hypoglycemia, so other therapies are expected to be combined with insulin. The literature reviewed in this review used two databases, PubMed and Cochrane, based on objectives, clinical keywords, and choice of articles according to predetermined inclusion and exclusion criteria. The methodology was a systematic approach involving identification, analysis, synthesis, evaluation, and comparison of relevant literature. A total of two results were obtained showing that the composite of insulin-based therapy and GLP-1 therapy in patients with type 2 DM provides effective results to control the levels of blood sugar in type 2 DM patients.

Downloads

Download data is not yet available.

References

Boer, G.A. and Holst, J.J. (2020) ‘Incretin Hormones and Type 2 Diabetes— Mechanistic Insights and Therapeutic Approaches’, Biology, 9(12), p. 473. Available at: https://doi.org/10.3390/biology9120473.

Drucker, D.J. et al. (2010) ‘Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits’, Diabetes Care, 33(2), pp. 428–433. Available at: https://doi.org/10.2337/dc09-1499.

Feng, W. et al. (2021) ‘Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies’, BMJ Open Diabetes Research & Care, 9(1), p. e002290. Available at: https://doi.org/10.1136/bmjdrc-2021-002290.

Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Vol. 7, Health Science Reports. John Wiley and Sons Inc; 2024.

International Diabetes Federation (2017) IDF Diabetes Atlas Eight Edition . 8th edn.

Kalra, S. et al. (2019) ‘Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force’, Diabetes Therapy, 10(5), pp. 1645–1717. Available at: https://doi.org/10.1007/s13300-019-0669-4.

Kementerian Kesehatan Republik Indonesia (2018) Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI 2018 . Jakarta.

Liu, F. et al. (2021) ‘Efficacy of once‐ daily glucagon‐ like peptide‐ 1 receptor agonist lixisenatide as an add‐ on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐ level pooled analysis of phase III studies’, Journal of Diabetes Investigation, 12(8), pp. 1386–1394. Available at: https://doi.org/10.1111/jdi.13504.

Louisa, M. et al. (2010) ‘Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials’, Medical Journal of Indonesia,

p. 205. Available at: https://doi.org/10.13181/mji.v19i3.406.

Mehta, A., Marso, S.P. and Neeland, I.J. (2017) ‘Liraglutide for weight management: a critical review of the evidence’, Obesity Science & Practice, 3(1), pp. 3–14. Available at: https://doi.org/10.1002/osp4.84.

Nauck, M.A. et al. (2021) ‘GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art’, Molecular Metabolism, 46, p. 101102. Available at: https://doi.org/10.1016/j.molmet.2020.101102.

Pathini, P.M.S.D. (2018) ‘Tren Terapi Diabetes dengan GLP-1 Receptor Agonist’,

Cermin Dunia Kedokteran, 45(4), pp. 291–296.

Perkumpulan Endokrinologi Indonesia (2015) Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. Jakarta: PB PERKENI.

Perkumpulan Endokrinologi Indonesia (2021) Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. Jakarta: PB PERKENI.

Pusat Informasi Obat Nasional (PIO Nas) (2023) Victoza, https://pionas.pom.go.id/.

Tack, C.J. et al. (2019) ‘Long‐ term efficacy and safety of combined insulin and glucagon‐ like peptide‐ 1 therapy: Evidence from the LEADER trial’, Diabetes, Obesity and Metabolism, 21(11), pp. 2450–2458. Available at: https://doi.org/10.1111/dom.13826.

Waldrop, G. et al. (2018) ‘Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis’, Journal of Diabetes and its Complications, 32(1), pp. 113–122. Available at: https://doi.org/10.1016/j.jdiacomp.2016.08.018.